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Autoimmune blistering diseases repre-
sent a group of rare, acquired disorders
characterized by overlapping features,
resistance to treatment, and potential
lethality. Relatively recent research in-
itiatives in laboratories throughout the
World have yielded notable advances in
the understanding of these diseases,
including their nosology, pathophysiol-
ogy, associations, and epidemiology.
These advances were almost exclusively
based on the study of affected patients
(i.e., applied translational research).
More specifically, light microscopy stu-
dies showed that the pemphigus group of
diseases was characterized by intraepi-
dermal blister formation resulting from
cell-cell dysadhesion, while the pemphi-
goid group of diseases was characterized
by subepidermal blister formation result-
ing from cell-matrix dysadhesion. Immu-
nofluorescence microscopy studies
showing that patients with these diseases
have in situ deposits of immunoreactants
in skin at the site of blister formation as
well as circulating autoantibodies that
bind normal human skin at the same sites
demonstrated that these disorders are
autoimmune in nature and characterized
by a specific loss of tolerance to auto-
antigens in skin (Figure 1). Studies
showing that autoantibodies were speci-
fic for patients with a given disease
allowed such immunoreactants to serve
as disease ‘‘markers’’ as well as probes
for the recovery, characterization, and
cloning of corresponding target autoanti-
gens. Interestingly, such target autoanti-
gens typically represent important
structural proteins in skin that mediate
either cell-cell or cell-matrix adhesion –
vital biological processes that have been
shown to be directly impaired by the
effect of patients’ autoantibodies. Immu-
nobullous disorders are among the best
understood autoimmune diseases in
man. Basic and translational research in
this field have advanced understanding
of autoimmunity and fostered the appli-
cation of new and advanced therapies.
The following articles review this subject
in detail and provide insights about the
future of research in this and related
content areas.
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Figure 1. Immunofluorescence microscopy studies of 1 M Nacl split skin allow regional mapping of
autoantibody reactivity against human epidermal basement membrane. Immunofluorescence
microscopy of 1 M NaCl split skin showing a site of focal separation within the epidermal basement
membrane delineated by type IV collagen (stained red) and bullous pemphigoid antigen 2 (stained green)
in the base and roof, respectfully, of the test substrate.Nuclei (counterstained blue) outline the overlying
epidermis as well as selected cells in the dermis.
MILESTONES | CUTANEOUS BIOLOGY OCTOBER 2008 E15
